12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Complera: Phase IIIb data

The open-label Phase IIIb STaR (Study 110) trial in 786 treatment-naïve patients with HIV infection showed that once-daily Complera met the primary endpoint of non-inferiority to Atripla emtricitabine/tenofovir/efavirenz in the proportion of patients who achieved HIV RNA levels <50 copies/mL at week 48 (86% vs. 82%, 95% CI for the difference: -1.1%, 9.2%). The predefined criterion for non-inferiority was a lower bound of a 2-sided 95% CI of -12%. In patients...

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >